HF specialists agree these drugs will be key tools in fighting the obesity-related HFpEF epidemic. Hurdles and questions ...

The improved engagement with HF patients intended to optimize GDMT was very modest, but did lead to increased use of MRAs.

Clinicians typically first turn to antiarrhythmic drugs, but switching up the order may be offer patients better outcomes.

CHICAGO, IL—Giving rivaroxaban (Xarelto; Bayer/Janssen) to adults under the age of 65, after an atrial fibrillation (AF) ...

Amidst discrepant SPRINT and ACCORD data, this study confirms the benefits seen in nondiabetics, Shawna Nesbitt says.

COVID-19 “magnified” preexisting disparities for rural patients as compared with their urban counterparts, one study author ...

Total and LDL cholesterol variability over time may be a biomarker for higher dementia risk and cognitive decline.

In high- and standard-risk patients CAS and TCAR look good, but some worry about skill sets, learning curves, and ...

The 2024 conference has 28 late-breakers plus plenty of basic and population science. More than anything, it’s a celebration.

While statins can reduce LDL levels and ASCVD events, high Lp(a) poses an independent risk that will need attention, too.

The latest version of the LLM had high concordance with a multidisciplinary heart team in choosing between PCI and CABG.

There’s no “silver bullet” for this problem, which is largely driven by clinical inertia, but some efforts are chipping away ...